<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Serotonin-norepinephrine reuptake inhibitor antidepressants: Pharmacokinetics</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Serotonin-norepinephrine reuptake inhibitor antidepressants: Pharmacokinetics</h1>
<div class="graphic"><div class="figure"><div class="ttl">Serotonin-norepinephrine reuptake inhibitor antidepressants: Pharmacokinetics</div><div class="cntnt"><table cellspacing="0"><colgroup span="8" width="12%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Bioavailability<br/> (%)</td> <td class="subtitle1">Time to peak plasma concentration<br/> (hours)</td> <td class="subtitle1">Primary metabolism*</td> <td class="subtitle1">Active metabolite(s)</td> <td class="subtitle1">Effect(s) on drug metabolism*</td> <td class="subtitle1">Elimination half-life<br/> (hours)</td> <td class="subtitle1">Clearance</td> </tr> <tr> <td>Desvenlafaxine</td> <td> <p>80</p> Unaffected by food</td> <td>7.5 to 9</td> <td>UGT glucuronidation</td> <td>No</td> <td>None</td> <td> <p>9 to 11</p> Prolonged in renal or hepatic impairment</td> <td> <p>Renal and hepatic; 45% excreted unchanged</p> Dose adjustment needed in renal or hepatic impairment</td> </tr> <tr> <td>Duloxetine</td> <td> <p>50</p> Wide interindividual variation (30 to 80); minimally affected by food</td> <td> <p>6 (unfed)</p> 10 (fed)</td> <td>CYP1A2, CYP2D6</td> <td>No</td> <td>Inhibits CYP2D6</td> <td> <p>10 to 12</p> Prolonged in hepatic impairment</td> <td> <p>Hepatic and renal; avoid in hepatic insufficiency (any degree), liver disease, or substantial alcohol use</p> Dose adjustment needed in renal impairment</td> </tr> <tr> <td>Levomilnacipran ER</td> <td> <p>&gt;90</p> Unaffected by food</td> <td> <p>6 to 8</p> Avoid concurrent administration with alcohol which can accelerate release of levomilnacipran from the extended-release preparation</td> <td>Primarily CYP3A4</td> <td>No</td> <td>None</td> <td> <p>12</p> Prolonged in moderate to severe renal impairment</td> <td> <p>Renal and hepatic; 50 to 60% excreted unchanged</p> Dose adjustment needed renal impairment</td> </tr> <tr> <td>Milnacipran</td> <td> <p>85 to 90</p> Unaffected by food</td> <td>2 to 4</td> <td>Glucuronidation</td> <td>No</td> <td>None</td> <td> <p>8 to 10</p> Prolonged in moderate to severe renal impairment and severe hepatic impairment</td> <td> <p>Renal and hepatic; 50 to 60% excreted unchanged</p> Dose adjustment needed in renal impairment</td> </tr> <tr> <td colspan="8">Venlafaxine</td> </tr> <tr> <td class="indent1">Immediate release</td> <td> <p>13<sup>¶</sup></p> Unaffected by food</td> <td>1 to 2</td> <td rowspan="2">CYP2D6, CYP3A4</td> <td rowspan="2">Yes (desvenlafaxine also known as O-dexmethylvenlafaxine or ODV)</td> <td rowspan="2">None</td> <td rowspan="2">5 (parent) <p>11 (active metabolite)</p> Prolonged in renal or hepatic impairment</td> <td rowspan="2"> <p>Renal and hepatic; ~34% excreted as active desvenlafaxine (ODV) or unchanged</p> Dose adjustment needed in renal or hepatic impairment</td> </tr> <tr> <td class="indent1">Extended release</td> <td> <p>45<sup>¶</sup></p> Unaffected by food</td> <td>5.5</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>CYP: cytochrome P450; UGT: uridine diphosphate glucuronosyltransferase.</p>
<p>* The classification of effects on drug metabolism are based upon US Food and Drug Administration (FDA) guidance.<sup>[1,2]</sup> Other sources may use a different classification system resulting in some agents being classified differently. Weak inhibitor effects are not listed. Clinically significant interactions can occasionally occur due to weak inhibitors, particularly if the target drug has a narrow therapeutic margin. Refer to the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program for a full review of potential interactions.</p>
¶ Oral bioavailability is increased by two- to threefold in mild to moderate hepatic impairment.</div><div class="graphic_reference">Data from:
<ol>
<li>Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26:39.</li>
<li>Yang LP, Plosker GL. Desvenlafaxine extended release. CNS Drugs 2008; 22:1061.</li>
<li>Thase ME. Venlafaxine and desvenlafaxine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, 5th ed, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Inc., Arlington 2017. p.515.</li>
<li>Norris S, Blier P. Duloxetine, milnacipran, and levomilnacipran. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, 5th ed, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington 2017. p.529.</li>
<li>Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
</ol>
<p class="extra_spacing_top">References:</p>
<ol>
<li>US Food and Drug Administration. Clinical drug interaction studies — Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry, January 2020. Available at: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions " target="_blank">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions</a> (Accessed on June 5, 2020).</li>
<li>US Food &amp; Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: FDA.gov website.</li>
</ol></div><div id="graphicVersion">Graphic 88063 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
